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Summary.-ICRF-187 was tested for cardioprotective activity in doxorubicin-
treated mice and guinea pigs. Pretreatment with i.p. ICRF-187 caused a significant
decrease in the incidence of i.v. doxorubicin-induced myocardial histological damage
in the mouse. I.p. ICRF-187 did not, however, reduce the effect ofi.p. doxorubicin on a
functional myocardial effect ofthis antitumour drug, a reduced histamine responsive-
ness of right atria in vitro. These data suggest that ICRF-187 may not be specific for
all the cardiac effects of doxorubicin.
DOXORUBICIN (ADRIAMYCIN®) is an
anthracycline antibiotic which has been
playing a significant and increasingly
important role in the treatment of cancer.
However, because of a cardiomyopathy
which it causes with increasing frequency
at high cumulative doses, it has been
necessary to limit the total amount of
doxorubicin to 550 mg/M2. The clinical
utility of the agent would probably
increase ifthis toxicity could be prevented
or reduced without alteration of chemo-
therapeutic activity. Recently, Herman
and colleagues have reported that ICRF-
187, the (+ )-isomer of ICRF-159 [(± )-1,-
2-bis (3,5,dioxopiperazinyl-1-yl) propane],
reduced cardiac damage in doxorubicin-
treated dogs (Herman & Ferrans, 1981)
and daunomycin-treated rabbits (Herman
et al. 1981). The present studies were
carried out to determine whether ICRF-
187 affords any protection against the
histological lesions caused by doxorubicin
in the mouse heart. Studies were also
conducted using guinea pigs to determine
if ICRF-187 would reduce a functional
effect of doxorubicin administration,
namely a reduced chronotropic response of
the right atrium to histamine in vitro.
METHODS
Mouse study.-Female Cox ICR mice were
obtained from Laboratory Animal Supply,
Indianapolis, Ind., U.S.A. The animals Nere
held in quarantine for 7 days and weighed 18-
22 g at the start of the study. Purina Rodent
Chow and water were permitted ad libitumn
throughout the study.
The experimental design was essentially as
described by Bertazzoli et al. (1979) with the
exception that the animals were injected i.p.
with ICRF-187 (50 mg/kg) or saline (10
ml/kg) 30 min before receiving doxorubicin
hydrochloride (4 mg/kg) or saline (10 ml/kg)
i.v. Group 1 animals received saline i.p. and
saline i.v., Group 2 saline i.p. and doxorubicin
i.v., and Group 3 ICRF-187 i.p. and
doxorubicin i.v. The animals were injected on
Tuesday and Friday ofWeeks 1, 2, 5, 6 and 7,
and killed by ether asphyxiation during week
11 ofthe study. Heartsandkidneys weretaken
at necropsy and fixed in 10%0 buffered
formalin. Routine paraffin sections (3 ,um) of
these organs were stained with haematoxylin
and eosin and examined microscopically for
damage. Severity of myocardial damage was
graded as follows:
Grade 1-very slighlt; scattered, single myo-
cardial fibres w%xith vacuolation or
degenerative changes.
Grade 2-slight; scattered small groups of
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altered myocardial fibres throughout the
atrial and ventricular myocardium.
Grade 3-moderate; disseminated myocardial
fibre vacuolation or degeneration with only
occasional focal unaffected areas.
Grade 4-marked; confluent groups of
affected myocardial fibres; most myo-
cardial fibres affected.
The x2 test was used to determine the signifi-
cance ofdifferences in lesion incidence among
treatment groups.
Guinea-pig studies.-Male Hartley strain
guinea pigs, (Davidson MillFarm, Jamesburg,
N.J., U.S.A.), weighing 258-369 g, were used
in these experiments. The animals were caged
individually with food and water permitted
ad libitum. They were randomly divided into
groups and after treatment, as defined below,
were killed by stunning and exsanguination.
The thoracic cavity was opened and the heart
was rapidly extirpated and placed in a dish
containing 95% 02 and 5% C02-bubbled
McEwan's solution (NaCl 7-60; KCl 0-42;
CaCl2, 0-24; NaHCO3, 2-10; NaH2PO4.H20,
0-142; glucose 2-00; sucrose 4-50 g/l) at
33-35°C. The right atrium was isolated and
suspended in a 10 ml isolated organ chamber
containing McEwan's solution aerated with
95% 02 and 5% C02 and maintained at
33-34CC. Atrial contraction was recorded
using a Grass FT.03 force displacement
transducer and a Beckman R612 Dynograph
recorder. The atria were permitted to acclima-
tize for 30 min before addition of 0-1 ml of a
3-64 x 10-4 mol/l histamine dihydrochloride
solution to each chamber to yield a bath
concentration of3-64 x 10-6mol/l. This dose of
histamine had previously been found to cause
an increase in atrial rate of approximately
80% ofmaximum. Atrial rate was determined
immediately before and 5 min after histamine
treatment and the change in atrial rate was
calculated for each preparation. Student's
non-paired t test was used to determine the
significance ofdifferences in basal rate and in
the histamine response of atria from control
and drug-treated animals.
Expt 1: Effect of doxorubicin.-One group
ofguinea pigs received a single i.p. injection of
1 mg/kg doxorubiciin weekly on Days 1, 8 and
15 of the study; the second group received 2
mg/kg weekly, on Days 1 and 8. Control
animals received saline (1 ml/kg) i.p. Animals
from each group were killed 4 days after each
injection ofdrug for the purpose of obtaining
the atria. Hearts and kidneys from 2 control
and 3 lmg/kg-doxorubicin-treated animals
from the last group killed were collected and
fixed in 10% buffered formalin. Routine
paraffin sections (3 ,um) of these organs,
stained with liaematoxylin and eosin, were
examined microscopically.
Expt 2:Effect ofICRF-187 anddoxorubicin.
-Each guinea pigreceived 2 i.p. injections on
Days 1, 8 and 15, either ICRF-187 (12-5
mg/kg) or saline (1 ml/kg) being injected 30
min before either doxorubicin (1 mg/kg) or
saline (1 ml/kg). Group 1 animals received
saline-saline, Group 2 saline-doxorubicin,
and Group 3 ICRF-187-doxorubicin. The
animals were observed and weighed daily and
were killed on Day 20 ofthe study.
Drugs-ICRF-187 (NSC169780, Lot No.
AD-01-81-1) was obtained from the National
Cancer Institute, Silver Springs, MD, U.S.A.
Histamine dihydrochloride was purchased
from Sigma Chemical Co., St Louis, MO.
U.S.A. Doxorubicin HCI was obtained from
Farmitalia Carlo Erba, Milan, Italy.
RESULTS
Mouse study
Results of the histological evaluation of
heart and kidney sections are summarized
in Table I. Control animals had no histo-
logical evidence ofmyocardial damage. In
contrast, focal myocardial damage was
found in 8/15 (53%) mice treated with
doxorubicin (4 mg/kg x 10). Six mice had
Grade 1 (very slight) and 2 had Grade 2
(slight) myocardial damage. Focal mono-
nuclear cellular infiltration was found in 2
of the 8 doxorubicin damaged hearts.
ICRF-187 (50 mg/kg, i.p.), administered
before each ofthe 10 doses ofdoxorubicin,
significantly reduced the incidence of
doxorubicin-induced myocardial damage
(P<0-05). Only 3/17 (18%) of the mice
treated with ICRF-187 and doxorubicin
had Grade 1 myocardial lesions.
The incidence of microscopic renal dam-
age was similar for each treatment group,
being 10, 13, and 6% in the control, saline-
doxorubicin, and ICRF-187-doxorubicin
groups respectively. Mice in both the sal-
ine-doxorubicin (28-6 + 3-4g; x + s.d.) and
the ICRF-187-doxorubicin (28-1 + 2-7 g)
groups weighed significantly less (P< 0-01)
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TABLE I.-Histopathological effects of doxorubicin on hearts and kidneys offemale mice
Heart
No. examined
Incidence of cardiac damage
No. hearts with:
Myocardial vaculoation
Grade I
Grade 2
Grade 3
Grade 4
Focal mononuclear cellular infiltration
Kidneys
No. examined
Incidence of renal damage
No. kidneys with:
Focal mineralization, papilla
Tubular basophilia
Cystic tubule
Treatment*
Saline i.p. Saline i.p. ICRF-187 i.p.
saline i.v. doxorubicin i.v. doxorubicin i.v.
10 15 17
0% 53% 1850t
0
0
0
0
0
10
1000
1
0
0
6
2
0
0
2
15
1300
0
1
1
3
0
0
0
0
17
6o
1
0
0
* Dosing schedule of Bertazzoli et al. (1979); twice weekly (Tuesday and Friday), Weeks 1, 2, 5, 6 and 7.
I.p. injections weregiven 30min before i.v. injections. The animals were killed duringWeek 11 ofthestudy.
t Significantly less than saline-doxorubicin; P < 0-05 (x2 test).
t Refer to Methods for description of grades of myocardial vacuolation.
than the control (34.5 + 5.4 g) animals at
the end of the experiment. The only
animal *to die during the experiment,
an animal in the ICRF-187-doxorubicin
group, died 3 days after receiving the
fourth pair of injections.
Guinea-pig studies
Results of an initial experiment to
determine the effect ofweeklyi.p. adminis-
tration of doxorubicin on the rate of
contraction and response to histamine of
atria mounted in vitro are summarized in
Table II. Administration of 1, 2 or 3 doses
of doxorubicin had no significant effect on
the intrinsic rate of contraction of the
atria. Significant reductions in the chrono-
tropic response to histamine (3.64 x 10-6
mol/l) were observed only after 2 weekly
injections of 2 mg/kg (-30.9%) and 3
weekly injections of 1 mg/kg (-27.3%)
doxorubicin. No evidence of vacuolar
cardiomyopathy in the heart or degener-
ative or inflammatory changes in the
cortex of the kidneys was found on
histological examination of these tissues
taken from 3 guinea pigs killed after the
third lmg/kg doxorubicin dose.
Results of the experiment to determine
the effect of ICRF-187 on doxorubicin-
induced functional effects on the atrium
are shown in TableIII. Theadministration
ofdoxorubicin (1 mg/kg) once a week for 3
weeks did not affect atrial rate, but
significantly reduced the chronotropic
response of the atria to histamine by
26x4% (P< 0.05). ICRF-187 did not block
this effect, the response of the atria taken
from the ICRF-187 and doxorubicin-
treated animals to histamine being
reduced by 35.6% compared with control
(P< 0x01). The control and ICRF-
187-doxorubicin-treated animals gained
spectively, 208 + 21 (x +s.d.) and 40 + 53 g
during the course of the study, while the
saline-doxorubicin treated animals lost an
average of 27 + 28 g. Two animals in the
saline-doxorubicin group died after
receiving the third dose ofdoxorubicin.
DISCUSSION
Data reported in this communication
support published reports (Herman &
Ferrans, 1981; Herman et al., 1981)
indicating that ICRF-187, the more water-
soluble (+) isomer of ICRF-159, reduces
myocardial histological damage induced
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TABLE III.-Contractile frequency and histamine responsiveness of isolated right atria
from doxorubicin and ICRF-187-doxorubicin-treated guinea-pigs
Dose
Treatment* (mg/kg i.p.)
Saline
Saline
Saline
Doxorubicin
ICRF-187
Doxorubicin
12-5
1
n
Contractile
frequency (beats/min)
. d %
xR + s.d. O/ A\
6 203+12-8
Av Frequency (beats/
min) to histamine§
x+s.d. %A
87 + 9 - 8 ---
1 6 180+13-7 -11-3 68+18-1 -26*4t
6 208+ 17-2 +2-5 56+ 17-2 -35-6t
* Animals treated weekly for 3 weeks. Injections given 30 min apart. Animals killed on Day 5 after third
treatment.
t Significantly less than control, P < 0-05.
t Significantly less than control, P < 0-01.
§ Bath concentration of histamine dihydrochloride, 3-64 x 10-6 mol/l.
by the chronic administration of anthra-
cyclines in animals. ICRF-187 signifi-
cantly reduced the incidence of
doxorubicin-induced histological cardiac
damage in mice when administered i.p.
30 min before doxorubicin. The dose of
ICRF-187 used was 12X5 times the dose of
doxorubicin, as it was in the dog study
reported by Herman & Ferrans (1981). It
is not known whether this is the optimum
ratio of ICRF-187 to doxorubicin. The
inability to completely block the cardio-
toxic response to doxorubicin suggests
that higher doses of ICRF-187 should be
examined. Also, the possibility exists that
doxorubicin has other cardiac effects
which result in focal or diffuse vacuolar
degeneration of myocardial fibres which
are not affected by ICRF-187.
Doxorubicin alters the electrical as well
as the contractile activity of the heart in
animals and man, and can cause con-
gestive heart failure (Ghione, 1978; Lenaz
& Page, 1976). Recent data, in addition
to our results, suggest that one way of
detecting functional myocardial effects of
doxorubicin is by stimulation ofthe heart.
Papish et al. (1981) found that evaluation
ofleft ventricular function in the presence
of a modest increase in systolic blood
pressure induced by i.v. methoxamine can
unmask abnormalities in doxorubicin-
treated patients with normal resting left
ventricular function. They reported that
50% of the patients receiving 415-485
mg/M2 doxorubicin had reduced left
ventricular function when stressed. Breed
et al. (1979), working in vitro with
electrically stimulated perfused hearts
taken from doxorubicin-treated rats,
found a dose-related decrease in maximal
apico-basal shortening, no increase in
shortening being observed after 12 weeks
of treatment. Data from our guinea-pig
experiments indicate that it is possible to
detect afunctional effect ofdoxorubicin on
atrial myocardium before histological
damage is evident. Chronic i.p. adminis-
tration ofdoxorubicin (2 mg/kg weekly for
2 weeks or 1 mg/kg weekly for 3 weeks)
caused a significant decrease in the in vitro
chronotropic response of right atria to
histamine. In guinea pigs treated weekly
with 1 mg/kg, basal atrial rate was not
altered and no histological myocardial
damage was observed.
To our knowledge, ICRF-187 has not
been tested to determine ifit will block or
reduce an effect of doxorubicin on cardiac
function. Data reported here indicate that
ICRF-187 will not block the effect of
doxorubicin on the chronotropic response
ofright atria to histamine. The significance
of this observation, and why this effect of
chronic doxorubicin administration, unlike
histological myocardial damage, was not
reduced by ICRF-187, remain to be
investigated.
Doxorubicin has been shown to have 2
distinctly different effects on cultured rat
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imyocardial cells, namely (1) nucleolar
fragmentation, segregation and chromatin
clumping and (2) inhibition of mitochon-
drial function (Lampidis et al. 1979). As
our data indicate that ICRF-1 87 will block
the histological but not the functional
effects of doxorubicin, it may be that
ICRF-187 blocks the nuclear, but not the
mitochondrial, or energy-related, effects of
this drug. Doxorubicin also reduces the
calcium-exchangeable fraction in spontan-
eously beating isolated guinea-pig atria
(Villani et al. (1978). Possibly this is the
effect of doxorubicin which relates to
reduced histamine responsiveness of the
atria and is not blocked by ICRF-187.
Herman & Ferrans (1981) noted that
ICRF-187 was not effective in blocking all
toxic responses to doxorubicin. Specifi-
cally, while effective against myocardial
histological damage, pretreatment with
ICRF-187 did not influence doxorubicin-
induced bone-marrow depression or
alopecia in dogs. Also, in the present
studies, ICRF-187 did not prevent the
adverse effects of doxorubicin on growth.
Thus, in addition to not having uniform
anti-doxorubicin toxocity activity in all
tissues, the data suggest that ICRF-187
may not be specific for all the cardiac
effects of doxorubicin. Pretreatment with
ICRF-187 reduced myocardial histological
damage in the mouse, but did not block
the functional effect of doxorubicin on
atrial responsiveness to histamine in the
guinea pig.
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